Could less medicine be just as good? prostate cancer study tests lower doses
NCT ID NCT05276492
Summary
This study aimed to find the lowest effective dose of the prostate cancer drug abiraterone. Researchers tested if taking a lower dose less frequently (like every other day or a few times a week) worked as well as the standard daily dose. The goal was to maintain cancer control while potentially reducing side effects and medication costs for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.